In mouse models of metabolic dysfunction-associated steatohepatitis (MASH), activation of peroxisome proliferator-activated receptor alpha (PPARα) has been shown to exert anti-inflammatory effects and may help address various stages of metabolic dysfunction-associated steatotic liver disease (MASLD) [87]. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.